What is the primary product AcuMedical is developing?

The primary product is the AcuRanger, described on slide 5 as an 'Advanced Device Platform.' It consists of specialized needle technology, a therapeutic and data collection device, and a cloud-based data-sharing center. The platform aims to standardize acupuncture data while reducing labor costs and session time for practitioners.

How does the company plan to navigate FDA regulations?

AcuMedical has a phased regulatory strategy outlined on slide 11. Year 1 focuses on obtaining the first 510(k) clearance for 'Model A' (Digital Electro-acupuncture) and a second for 'Type-I' needles. Year 2 targets a third 510(k) for 'Model B' with data collection, and Year 3 involves clearance for 'Model C' and thermal therapy needles.

What is the specific financial ask and its intended use?

According to slide 13, AcuMedical is raising $2M for a 24-month financing plan. The largest portion, 56%, is earmarked for manufacturing. The remainder is split between clinical trials (19%), research and development (13%), and marketing (12%).

Who are the intended customers for the AcuRanger platform?

Slide 9 divides the target market into individuals and institutions. Individuals include 45,000 chiropractors, 240,000 physical therapists, 130,000 occupational therapists, and acupuncture practitioners in the US and China. Institutions include cancer centers, rehab clinics, and traditional Chinese medicine facilities.

What evidence is provided for the efficacy of their solution?

Slide 3 presents a line graph comparing a 'Morphine Group' to an 'Acupuncture Group.' The data suggests that the acupuncture group achieved lower pain scores over a 60-minute period. The slide also notes that needle therapies are a 'recommended non-pharma therapy by FDA' and useful for opiate rehabilitation.

AcuMedical Inc. Pitch Deck (2017): 17-Slide Seed Deck

See all 17 slides of the AcuMedical Inc. pitch deck — a 2017 deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

AcuMedical Inc. presents a compelling case for the AcuRanger, a digital electro-acupuncture device designed to disrupt the pain management sector. By framing acupuncture as a clinically superior alternative to morphine and a tool for opiate rehab, the company targets a massive $60.20 billion global therapeutics market. The deck is structured around a clear three-year milestone plan, emphasizing the need for multiple FDA 510(k) clearances. While the deck lacks a dedicated internal management team slide, it leans heavily on a high-pedigree advisory board with experience from Medtronic, Abbott,…

Key takeaways

The company positions acupuncture as more effective and sustainable than morphine, citing a pain score graph on slide 3.
AcuMedical identifies a massive TAM, including a $60.20B global pain management therapeutics market and a $3.2B device market on slide 7.
The product strategy involves a tiered launch of Model A, B, and C devices, each requiring separate 510(k) clearances as detailed on slide 11.
Revenue targets are explicitly stated: $2.5M in Year 2 and $10M in Year 3 on slide 11.
The $2M fundraising ask is clearly broken down, with 56% dedicated to manufacturing and 19% to clinical work on slide 13.
The deck highlights a strong advisory board with veterans from Medtronic, Boston Scientific, and the China Association of Acupuncture-Moxibustion on slide 15.
The target market is segmented into 45k US acupuncture practitioners and 179k in China, alongside 240k physical therapists on slide 9.
There is a significant omission of the core founding team's operational roles, focusing instead on external advisors on slide 15.

Slide 1: Title and Vision

The deck opens with a clear value proposition: "Manage Pain with AcuRanger®." The imagery uses medical icons (stethoscopes, pills, patient silhouettes) and a global map, signaling both a clinical focus and international ambitions. The branding for AcuMedical, Inc. is prominent, establishing the company identity immediately.

Slide 3: The Problem and Solution Framework

Slide 3, titled "SOLUTION – NEEDLE THERAPIES," attempts to validate acupuncture through a Western medical lens. It includes a pain score graph comparing acupuncture to morphine, showing a steeper decline in pain for the acupuncture group over 60 minutes. Key claims include that it is "effective and safer" and a "recommended non-pharma therapy by FDA." Crucially, this slide addresses the business model by listing reimbursement rates: $60-$400 per procedure for regular/electro-acupuncture, and mentions the potential for a new reimbursement code.

Slide 5: The AcuRanger Platform

This slide introduces the hardware and software components. The "Advanced Device Platform" includes needle technology, a data collection device (shown as a sleek, white medical cart with a touchscreen), and a cloud-based sharing center. The benefits listed are operational: reduced session time, lower labor costs, and data collection standardization. The inclusion of a software interface screenshot (labeled "AcuCloud") suggests the product is beyond the conceptual stage and has a functional UI for tracking patient protocols.

Slide 7: Market Opportunity

AcuMedical uses a classic TAM (Total Addressable Market) visualization on slide 7. They cite a $60.20 billion Global Pain Management Therapeutics market and a $3.2 billion Global Pain Management Devices market. To provide social context, the slide features a heat map of the United States titled "Overwhelming Retail Opioid Prescriptions," sourced from the CDC and DEA. This positions the AcuRanger not just as a medical tool, but as a solution to a public health crisis.

Slide 9: Customer Segmentation

Slide 9 provides specific numbers for the target market. It breaks down "Individual" customers into 45,000 chiropractors, 240,000 physical therapists, and 130,000 occupational therapists. It also highlights a massive international opportunity with 179,000 acupuncture practitioners in China compared to 45,000 in the US. The "Institutions" column lists cancer centers and rehab clinics, showing a broad B2B sales strategy.

Slide 11: The Three-Year Roadmap

The "Key Target Milestones" slide is one of the most detailed in the deck. It outlines a clear path to market:

Year 1: Production readiness for Model A and Type-I needles, pending 510(k) clearances (expected in 6-12 months), and a cloud service pilot. · Year 2: Target revenue of $2.5M, launch of Model B (data collection), and entry into Asian markets (Singapore, Hong Kong, China). · Year 3: Target revenue of $10M, launch of Model C (thermal therapy), and a subsequent fundraising round for AI and VR features.

Slide 13: The $2M Ask

The financing plan is straightforward. AcuMedical is seeking $2M to cover a 24-month runway. The pie chart shows a heavy lean toward execution: 56% for manufacturing, 19% for clinical, 13% for R&D, and 12% for marketing. This distribution suggests the company has finished initial prototyping and is focused on scaling production and clinical validation.

Slide 15: Advisory Board

Instead of a traditional team slide, slide 15 showcases an "Advisory Board." The pedigree is high, featuring Dr. Walter H. Olson (VP Emeritus at Medtronic), Mark Strong (former VP at HeartWare and Boston Scientific), and Dr. Li Gu (former Deputy Secretary-General of China Association of Acupuncture-Moxibustion). The logos of Harvard Medical School, MIT, and Abbott are used to bolster credibility. However, the lack of a slide detailing the full-time management team is a notable omission for a $2M raise.

Slide 17: Contact Information

The deck concludes with a "Thank You" slide providing contact details for Charlie Chen, including a phone number, email, and website URL. This serves as the call to action for interested investors.

What AcuMedical Does Well

AcuMedical excels at framing a traditional practice (acupuncture) as a modern, data-driven medical technology. By explicitly linking their product to the opioid crisis and FDA recommendations, they move the conversation away from "alternative medicine" and into "clinical therapeutics." The regulatory roadmap on slide 11 is exceptionally clear, providing investors with a measurable timeline for risk reduction through 510(k) clearances. Furthermore, the market segmentation on slide 9 shows a sophisticated understanding of who will actually buy the device, moving beyond vague "healthcare" labels to specific practitioner counts.

What Is Missing from the Deck

The most glaring omission is the core management team. While the advisors are impressive, investors fund founders, not just advisors. There is no information on who is running the day-to-day operations, their previous exits, or their technical expertise. Additionally, the deck lacks unit economics. While reimbursement rates are mentioned, the cost to manufacture the AcuRanger and the projected sales price are missing. There is also no mention of existing intellectual property or patent status, which is critical for a medical device company. Finally, while Year 2 and 3 revenue targets are provided, there is no evidence of current traction or pre-orders to justify those projections.

Founder Takeaways: What to Copy

Use a Phased Regulatory Roadmap: If your startup requires FDA or other regulatory approvals, copy the structure of slide 11. Breaking down specific models (A, B, C) and their corresponding clearance timelines shows that you understand the complexity of the medical market. Contextualize the Problem: AcuMedical doesn't just say "pain is bad." They use a heat map of opioid prescriptions (slide 7) to show the urgency of the problem. Using third-party data to illustrate a macro trend makes your solution feel inevitable. Segment Your TAM: Instead of claiming a trillion-dollar market, slide 9 breaks the market down by specific job titles and geographies. This makes the sales strategy feel grounded and achievable.

Frequently asked questions

What is the primary product AcuMedical is developing?: The primary product is the AcuRanger, described on slide 5 as an 'Advanced Device Platform.' It consists of specialized needle technology, a therapeutic and data collection device, and a cloud-based data-sharing center. The platform aims to standardize acupuncture data while reducing labor costs and session time for practitioners.
How does the company plan to navigate FDA regulations?: AcuMedical has a phased regulatory strategy outlined on slide 11. Year 1 focuses on obtaining the first 510(k) clearance for 'Model A' (Digital Electro-acupuncture) and a second for 'Type-I' needles. Year 2 targets a third 510(k) for 'Model B' with data collection, and Year 3 involves clearance for 'Model C' and thermal therapy needles.
What is the specific financial ask and its intended use?: According to slide 13, AcuMedical is raising $2M for a 24-month financing plan. The largest portion, 56%, is earmarked for manufacturing. The remainder is split between clinical trials (19%), research and development (13%), and marketing (12%).
Who are the intended customers for the AcuRanger platform?: Slide 9 divides the target market into individuals and institutions. Individuals include 45,000 chiropractors, 240,000 physical therapists, 130,000 occupational therapists, and acupuncture practitioners in the US and China. Institutions include cancer centers, rehab clinics, and traditional Chinese medicine facilities.
What evidence is provided for the efficacy of their solution?: Slide 3 presents a line graph comparing a 'Morphine Group' to an 'Acupuncture Group.' The data suggests that the acupuncture group achieved lower pain scores over a 60-minute period. The slide also notes that needle therapies are a 'recommended non-pharma therapy by FDA' and useful for opiate rehabilitation.

Cover slide of the AcuMedical Inc. pitch deck — Seed/Early Stage 2017 — AcuMedical Inc. pitch deck, slide 1 (2017)

AcuMedical Inc. pitch deck: the facts

Company: AcuMedical Inc.
Year: 2017 (based…
Stage: Seed/Early Stage
Slides: 17
Sector: Medical Devices / HealthTech
Deck type: Investor Pitch Deck
Headquarters: USA (based on 651 area code on slide 17)

AcuMedical Inc. pitch deck PDF

The full AcuMedical Inc. deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the AcuMedical, Inc. pitch deck was used for

This is a 17‑slide seed/early‑stage pitch deck from around 2017 for AcuMedical, Inc., a medical device/healthtech company developing the AcuRanger platform for data‑driven needle‑based therapies as a non‑pharmacological alternative to opioids. The deck positions AcuRanger as an advanced electro‑therapy/acupuncture device platform that captures treatment data, guides therapy, and integrates with EMR and reimbursement workflows. The raise described in the deck is a $2M seed/early round to scale manufacturing, pursue FDA regulatory approvals, and expand clinical and commercial efforts for pain management indications. At the time of the deck, the company is targeting pain management, opioid rehab, and broader clinical use of needle therapies with reimbursement support.

Round: Seed / Early Stage
Founders: Charlie Chen
Industry: Medical Devices / HealthTech

Year: 2017 (based on the deck’s copyright and context)

Raising: $2M (seed/early‑stage round described in the deck, for manufacturing scale‑up, regulatory work, and clinical/commercial expansion)

Use of funds as presented: Funds are allocated to scaling manufacturing of AcuRanger devices, supporting FDA regulatory approvals, and expanding clinical deployment and commercial efforts in pain management and opioid rehab settings.

What the AcuMedical, Inc. deck got right

Compelling positioning around opioid crisis and non‑pharmacologic pain management. The deck presents a clear clinical and societal focus by positioning AcuRanger as a **data‑driven, non‑pharmacological alternative to opioids**, directly addressing the opioid crisis and pain management needs. This framing taps into strong regulatory and public‑health momentum around non‑opioid therapies.
Differentiated product with integrated hardware, data, and workflow features. AcuRanger is described as an **advanced device platform** that goes beyond standard acupuncture and electro‑therapy, offering computerized low‑frequency stimulation, focalized micro‑energy delivery, therapy guidance, data collection, potential AI capabilities, and EMR/reimbursement support. This combination of hardware and data features creates a differentiated value proposition.
Alignment with FDA guidance and reimbursement economics. The deck explicitly highlights that needle therapies are considered effective, safer, and recommended as non‑pharmacologic options by the FDA, and that they can be used for opioid rehab, with existing reimbursement ranges and potential new codes. By tying the solution to FDA recommendations and reimbursement, the company strengthens perceived regulatory and economic viability.
Clear articulation of procedure economics and revenue potential. The presentation includes clear economic framing, citing typical reimbursement per procedure ($60–$400) and connecting this to projected revenue growth and business model assumptions over a five‑year horizon. This helps investors understand how clinical use translates into revenue.
Effective comparative framing versus traditional acupuncture and standard electro‑therapy. The deck contrasts AcuRanger’s focalized, data‑rich micro‑energy stimulation with regular acupuncture and standard electro‑therapy, making the product’s advantages tangible for non‑technical investors. The simple comparative framing clarifies why a new device platform is needed.
Visible leadership and contact accessibility through named COO/co‑founder. The final slide includes direct contact details for **Charlie Chen**, identified externally as COO and co‑founder of AcuMedical, which underscores that a named operational leader is actively fronting the raise and is accessible to investors.

What could have been stronger

Limited presentation of rigorous clinical evidence for AcuRanger itself. The deck does not present externally validated clinical data (e.g., randomized controlled trials, published studies) demonstrating the efficacy or opioid‑sparing impact of AcuRanger beyond general claims about needle therapies being effective and safer than opioids. This makes it difficult for investors to assess clinical differentiation and evidence‑based outcomes versus standard acupuncture or competing devices.
Regulatory pathway and status are high‑level and lack specific milestones. While the deck references FDA recommendations for non‑pharmacologic therapy and outlines an intended FDA approval path, it does not clearly specify the exact regulatory classification, device type, timeline, or current status (e.g., 510(k) submission, IDE, completed trials). Without precise regulatory milestones, investors cannot fully gauge approval risk or readiness.
Reimbursement assumptions lack detailed payer and coding validation. The deck cites reimbursement ranges of $60–$400 per procedure and mentions a potential new reimbursement code, but does not detail which specific CPT codes, payers, or confirmed coverage policies will apply to AcuRanger. This leaves reimbursement assumptions and revenue forecasts under‑substantiated from a payer‑validation perspective.
Data and AI capabilities described conceptually but not evidenced with pilots or integrations. Although the deck positions AcuRanger as a data‑capable, potentially AI‑enabled platform that integrates with EMRs, it does not show concrete examples of data outputs, analytics, or validated AI features, nor does it reference any pilot integrations with major EMR vendors. For a data‑driven platform, the absence of specific data workflows or proof‑of‑concept deployments is a notable gap.
Competitive analysis is narrow and does not fully address advanced device competitors. The competitive landscape in the deck centers on contrasting AcuRanger with regular acupuncture and standard electro‑therapy, but does not systematically map direct competitors in the advanced electro‑therapy or digital pain‑management device space, nor does it compare pricing, regulatory status, or adoption of those alternatives. This limits investors’ ability to evaluate competitive risk and differentiation.

How an investor would read this deck

What draws attention

Evidence that needle‑based and electro‑therapy interventions meaningfully reduce opioid use or dosage in relevant pain indications, ideally via published studies or ongoing trials tied directly to AcuRanger or similar protocols.
Regulatory classification and pathway for AcuRanger, including device type, required clinical data, and a realistic timeline and budget for FDA clearance or approval.
Validation of reimbursement claims (specific CPT codes, payer coverage, and billing workflows) and how AcuRanger’s data capture and EMR integration concretely support reimbursement documentation.
Clinical traction metrics such as number of installed devices, patient treatments delivered, key reference sites, and outcomes data, beyond forward‑looking revenue projections.
Strength and depth of the team, particularly regulatory, clinical, and commercial leadership beyond the identified COO/co‑founder Charlie Chen.

Risks that stand out

Regulatory risk if AcuRanger requires more extensive clinical evidence than anticipated to obtain FDA clearance or approval, lengthening timelines and increasing capital requirements beyond the $2M seed raise.
Clinical adoption risk if pain specialists and rehab programs are slow to adopt advanced electro‑therapy devices or remain skeptical without robust opioid‑sparing data specific to AcuRanger.
Reimbursement risk if anticipated procedure pricing and potential new reimbursement codes are delayed, denied, or limited to certain indications or payers, reducing achievable revenue per treatment.
Competitive risk from other non‑opioid pain therapies (pharmacologic and non‑pharmacologic) and more established neuromodulation or electro‑therapy device companies with existing regulatory approvals and payer relationships.
Execution risk around building and maintaining a sophisticated, data‑driven device platform (including EMR integration and potential AI features) with a relatively small early‑stage team and limited capital.

Questions this deck invites

Which specific FDA device classification and regulatory pathway (e.g., 510(k), De Novo) is AcuRanger pursuing, and what is the current status of submissions and interactions with the agency?
What clinical evidence (studies, pilot data, or ongoing trials) exists that directly evaluates AcuRanger or its treatment protocols in terms of pain reduction and opioid‑sparing outcomes, and where has it been conducted?
Which CPT codes, payer policies, or reimbursement mechanisms are currently used to bill AcuRanger procedures, and what payer feedback or coverage decisions have been obtained to date?
How many AcuRanger units have been manufactured, deployed, and used in clinical settings, and what usage and revenue metrics can be shared from these early deployments?
What is the data architecture for AcuRanger (data types collected, storage, security, analytics), and are there any live EMR integrations or AI‑driven decision‑support features in current use versus those planned?

What founders can take from the AcuMedical, Inc. deck

Positioning a device platform as a **non‑pharmacological alternative to opioids** is compelling when tied to broader public‑health concerns, but investors will expect specific clinical data and regulatory clarity to support such claims.
Highlighting **reimbursement mechanics and procedure‑level economics** (e.g., $60–$400 per treatment and potential new billing codes) can strengthen a medical device pitch, provided these assumptions are backed by clear coding and payer evidence.
Differentiating a new device versus “standard of care” therapies (regular acupuncture and standard electro‑therapy) by emphasizing **data collection, computerized guidance, and integration with EMR** can frame strong product positioning, but requires concrete demonstrations and pilots to be fully co
Explicitly stating a **fundraising target and intended use of funds** (here, a $2M seed/early raise for manufacturing, regulatory, and clinical expansion) helps investors understand capital needs and milestones, especially in regulated healthtech domains.
Including direct contact information and a clear leadership role (e.g., COO and co‑founder contact on the final slide) facilitates investor follow‑up and can signal accessibility and commitment from the founding team.
Framing needle therapies as **FDA‑recommended non‑pharma options** and useful for opioid rehab aligns the product with emerging guidelines favoring non‑opioid therapies, but subsequent pitches should link these macro trends explicitly to the device’s own evidence and regulatory path.

AcuMedical, Inc. pitch deck: common questions

What does AcuMedical, Inc. do?

AcuMedical, Inc. is a medical device/healthtech company developing **AcuRanger**, an advanced electro‑therapy/acupuncture platform designed to provide data‑driven, non‑pharmacological pain management as an alternative to opioids. The system focuses on focalized micro‑energy stimulation with computerized guidance and data collection to support safer, more sustainable needle‑based therapies.

How much was AcuMedical raising in this pitch deck and for what purposes?

According to the pitch deck, AcuMedical is raising **$2M** in this seed/early‑stage round to scale manufacturing of the AcuRanger device, support FDA regulatory activities, and fund clinical and commercial expansion for pain management and opioid rehab use cases. This is explicitly framed as an early fundraising round tied to regulatory progress and market entry.

What problem is AcuMedical trying to solve and what is its proposed solution?

The deck identifies **needle therapies (acupuncture and electro‑therapy)** as the core solution, emphasizing that they are effective, safer than opioids, recommended as non‑pharma therapies by the FDA, useful for opioid rehab, and supported by existing and potential new reimbursement codes for procedures priced roughly $60–$400. AcuRanger builds on these therapies with computerized, focalized micro‑energy stimulation, data capture, and therapy guidance.

Who are AcuMedical’s target customers for AcuRanger?

The pitch deck targets pain management clinicians, opioid rehab programs, and broader healthcare institutions interested in non‑pharmacological therapies, highlighting reimbursement ranges ($60–$400 per procedure) and the prospect of a new reimbursement code for advanced electro‑therapy. The company also references international expansion plans and FDA approval pathways, suggesting a focus on U.S. and global hospital/clinic markets.

How is AcuRanger different from traditional acupuncture or standard electro‑therapy devices?

The deck presents AcuRanger as an **advanced device platform** offering computerized low‑frequency stimulation that mimics manual needle manipulation, focalized micro‑energy delivery, and integrated data collection. It contrasts this with regular acupuncture and standard electro‑therapy, which rely on static needle placement or basic low‑frequency stimulation and patient feedback without digital data or decision support.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

AcuMedical Inc. pitch deck slides

AcuMedical Inc. pitch deck slide 1 of 17 — AcuMedical Inc. pitch deck — slide 1 of 17

AcuMedical Inc. pitch deck slide 2 of 17 — AcuMedical Inc. pitch deck — slide 2 of 17

AcuMedical Inc. pitch deck slide 3 of 17 — AcuMedical Inc. pitch deck — slide 3 of 17

AcuMedical Inc. pitch deck slide 4 of 17 — AcuMedical Inc. pitch deck — slide 4 of 17

AcuMedical Inc. pitch deck slide 5 of 17 — AcuMedical Inc. pitch deck — slide 5 of 17

AcuMedical Inc. pitch deck slide 6 of 17 — AcuMedical Inc. pitch deck — slide 6 of 17

What each slide of the AcuMedical Inc. pitch deck says

Slide 2

py WHY IS PAIN - MANAGEMENT CRITICAL? a — * Increasing i = Opioid Prescriptions = Prescription Overdoses oe 4 = Growing Addiction 504 billion 3 > < prescription opioids’

Slide 3

~ SOLUTION — . NEEDLE THERAPIES / ) 3 * Effective and safer Ih * Recommended non-pharma therapy by FDA | ps * Useful for opiate rehab go N —— * More effective and sustainable than morphine i * Reimbursement is available: j J) " I~ 1 * Regular/Electro: $60-$400 per procedure / PT Re * Potential new reimbursement code = we. [EH

Slide 4

Regular Acupuncture Standard Electro- Pdyaeead Cevics Therapy (SET) Platform Peulent ete N] ‘ tL nS 2 [| ) «Low-frequency stimulation to v' Computerized SET is mean mimic needle maneuyer v Focalized micro-energy stimulation Glace ea * Require patient feedback on ¥ Data collection capability output energy setting 7 Teh ° v" Potential Al ¥" Personal records ¥" Supports EMR and reimbursement ne

Slide 5

‘&) AcuMedical & ADVANCED DEVICE y ~/ PLATFORM % 7 7 * Needle Technology p ls s_— * Therapeutic and Data Collection < Acdglel pA Device — * Cloud-Based Data-Sharing Center Benefits: pre * Effective and safer therapy : i = * Increased patient comfort " * Reduced session time and labor cost EE * Data collection standardization — ACUMEDICAL, 7